Cargando…

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy

PURPOSE: To assess the efficacy and safety of switching from prostaglandin analog (PGA) monotherapy to tafluprost/timolol fixed-combination (Taf/Tim) therapy. SUBJECTS AND METHODS: Patients with primary open-angle glaucoma, normal-tension glaucoma, or ocular hypertension who had received PGA monothe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitamura, Kazuyoshi, Chiba, Tatsuya, Mabuchi, Fumihiko, Ishijima, Kiyotaka, Omoto, Shu, Kashiwagi, Fumiko, Godo, Takashi, Kogure, Satoshi, Goto, Teruhiko, Shibuya, Takashi, Tanabe, Jhoji, Tsukahara, Shigeo, Tsuchiya, Tadaharu, Tsumura, Toyoaki, Tokunaga, Takaharu, Hosaka, Osamu, Saito, Tetsunori, Kashiwagi, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841029/ https://www.ncbi.nlm.nih.gov/pubmed/29675274 http://dx.doi.org/10.1155/2018/8456764

Ejemplares similares

Changes in adherence and associated factors among patients on newly introduced prostaglandin analog and timolol fixed-combination therapy
por: Hasebe, Yuka, et al.
Publicado: (2018)

Switching from concomitant therapy to tafluprost/timolol fixed combination
por: Inoue, Kenji, et al.
Publicado: (2018)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2018)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto, Kenji, et al.
Publicado: (2018)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi, Hideaki, et al.
Publicado: (2017)

Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study
por: Bourne, Rupert Richard Alexander, et al.
Publicado: (2019)

Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination
por: Kurysheva, Natalia Ivanovna
Publicado: (2019)

Green HPLC method with time programming for the determination of the co-formulated eye drops of tafluprost and timolol in their challengeable ratio
por: Abd-AlGhafar, Walaa Nabil, et al.
Publicado: (2022)

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
por: Holló, Gábor, et al.
Publicado: (2014)

Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops
por: Seo, Du Ri, et al.
Publicado: (2015)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate, Ngamkae, et al.
Publicado: (2020)

Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes
por: Ansari, E., et al.
Publicado: (2022)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy
por: Oddone, Francesco, et al.
Publicado: (2022)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
por: Ansari, Ejaz, et al.
Publicado: (2021)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
por: Garcia-Medina, Jose J., et al.
Publicado: (2022)

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis in a COVID-19 patient: A case report
por: Kogure, Chio, et al.
Publicado: (2021)

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
por: Takagi, Yasutaka, et al.
Publicado: (2016)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat, Lutz E, et al.
Publicado: (2017)

Lysyl oxidase-like 1 gene polymorphisms in Japanese patients with primary open angle glaucoma and exfoliation syndrome
por: Mabuchi, Fumihiko, et al.
Publicado: (2008)

Lack of association between p53 gene polymorphisms and primary open angle glaucoma in the Japanese population
por: Mabuchi, Fumihiko, et al.
Publicado: (2009)

Comparison of Latanoprost/Timolol with Carbonic Anhydrase Inhibitor and Dorzolamide/Timolol with Prostaglandin Analog in the Treatment of Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2014)

Effects of Tafluprost on Ocular Blood Flow
por: Zhang, Xinyue, et al.
Publicado: (2022)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer, Anton, et al.
Publicado: (2011)

Changes in Peripheral Anterior Chamber Depth of a Case of Relapsing Polychondritis with Recurrent Secondary Angle Closure Glaucoma§
por: Kashiwagi, Kenji, et al.
Publicado: (2008)

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
por: Rolle, Teresa, et al.
Publicado: (2017)

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients
por: Tsumura, Toyoaki, et al.
Publicado: (2014)

Efficacy and Safety of Switching Latanoprost Monotherapy to Bimatoprost Monotherapy or Combination of Brinzolamide and Latanoprost
por: Imasawa, Mitsuhiro, et al.
Publicado: (2016)

Impact of Patient Access to Internet Health Records on Glaucoma Medication: Randomized Controlled Trial
por: Kashiwagi, Kenji, et al.
Publicado: (2014)

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
por: Pfeiffer, Norbert, et al.
Publicado: (2014)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
por: Park, Sang-Woo, et al.
Publicado: (2022)

24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2016)

Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost
por: Tokuda, Naoto, et al.
Publicado: (2017)

Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog
por: Niwano, Yoshimi, et al.
Publicado: (2014)

Correction to: 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy
por: Konstas, Anastasios-Georgios, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bvo6pif7ltf70kjp1mub8qg3lv